Bioactive Compounds and Health Benefits of<i>Artemisia</i>Species

Nigam, Manisha; Atanassova, Maria; Mishra, Abhay Prakash; Pezzani, Raffaele; Devkota, Hari Prasad; Plygun, Sergey; Salehi, Bahare; Setzer, William N.; Sharifi‐Rad, Javad

doi:10.1177/1934578x19850354

Cited by 138 publications

(151 citation statements)

References 107 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…Moreover, A. vulgaris is consumed orally by local citizens as a traditional herbal for fever, headache, and stomachache. To the best of our knowledge, there has been no toxicity reported from citizens consuming A. vulgaris so far [ 48 ].…”

Section: Discussionmentioning

confidence: 99%

Artemisia vulgaris efficacies against various stages of Aedes aegypti

et al. 2020

View full text Add to dashboard Cite

Background and Aim: Aedes aegypti is the vector of dengue fever, dengue hemorrhagic fever, chikungunya, and, most recently, Zika. Dengue fever is one of Indonesia's endemic diseases. The principal tool for preventing dengue is controlling Ae. aegypti by chemical insecticides since vaccine against dengue is still under research. However, Ae. aegypti developed resistance to various chemical insecticides worldwide. Therefore, research on alternate compounds as mosquito insecticides is urgently needed. This study demonstrated the efficacy of Artemisia vulgaris extract as larvicidal, ovicidal, adulticidal, repellency, and oviposition deterrent activity against Ae. aegypti. Materials and Methods: A. vulgaris was obtained from Temanggung, Indonesia, while the eggs of Ae. aegypti were collected from Yogyakarta, Indonesia, and were hatched in Laboratory of Parasitology, Faculty of Veterinary Medicine, Universitas Gadjah Mada. Larvicidal activity was evaluated according to the WHO protocol; adulticidal activity was performed using the Centers for Disease Control protocol. Oviposition activity was evaluated using ovitraps added with A. vulgaris extract, complete protection time in the repellent assay was defined as the number of minutes elapsed between compound application and the landing of the first mosquito. Results: A test of the larvicidal activity of A. vulgaris extract returned an LC50 of 65.8 ppm (r2=0.9014) in 1 h and 18.6 ppm (r2=0.575) in 24 h. A. vulgaris was effective as an adulticidal, demonstrating LC50 values of 11.35 mg (r2=0.875) in 90 min, 9.63 mg (r2=0.924) in 105 min, and 6.46 mg (r2=0.925) in 120 min. A. vulgaris at a concentration of 1000 ppm was able to reach 96% of oviposition deterrent effect. The ovicidal assay, a concentration of 1000 ppm resulted in 82.67% of eggs remaining unhatched. An extract concentration of 80 mg/ml achieved 63.3±3.5% biting repellency in adults. Conclusion: This study gives a clear indication that A. vulgaris extract acts on Ae. aegypti at various developmental stages and is a potential alternative bioinsecticide for controlling this disease vector.

show abstract

Section: Discussionmentioning

confidence: 99%

Artemisia vulgaris efficacies against various stages of Aedes aegypti

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Although these are two different species, it has been shown that within the Artemisia genus, many compounds are conserved; however, it is the small chemical nuances and profile that have a large effect on the biological activity (Abad et al, 2012). Medicinal plants species that are closely related may also produce similar or chemically similar compounds responsible for their biological activity (Nigam et al, 2019). This forms the basic definition for chemotaxonomy, which is the "closely related plants contain the same or similar chemical profiles" (Hao and Xiao, 2020).…”

Section: Potential Leads From Southern African Plantsmentioning

confidence: 99%

Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19)

et al. 2020

View full text Add to dashboard Cite

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), known to cause the disease COVID-19, was declared a pandemic in early 2020. The objective of this review was to collate information regarding the potential of plants and natural products to inhibit coronavirus and targets associated with infection in humans and to highlight known drugs, which may have potential activity against SARS-CoV-2. Due to the similarity in the RNA genome, main proteases, and primary host receptor between SARS-CoV and SARS-CoV-2, a review was conducted on plants and secondary metabolites, which have shown activity against SARS-CoV. Numerous scientific reports on the potential of plants and secondary metabolites against SARS-CoV infection were found, providing important information on their possible activity against SARS-CoV-2. Based on current literature, 83 compounds have been identified with the potential to inhibit COVID-19. The most prominent selectivity was found for the alkaloid, lycorine, the lignan, savinin, and the abietane terpenoid, 8-beta-hydroxyabieta-9(11),13-dien-12-one with selectivity index values greater than 945, 667, and 510, respectively. Plants and their secondary metabolites, with activity against targets associated with the SARS-CoV infection, could provide valuable leads for the development into drugs for the novel SARS-CoV-2. The prospects of using computational methods to screen secondary metabolites against SARS-CoV targets are briefly discussed, and the drawbacks have been highlighted. Finally, we discuss plants traditionally used in Southern Africa for symptoms associated with respiratory viral infections and influenza, such as coughs, fever, and colds. However, only a few of these plants have been screened against SARS-CoV. Natural products hold a prominent role in discovering novel therapeutics to mitigate the current COVID-19 pandemic; however, further investigations regarding in vitro, in vivo, pre-clinical, and clinical phases are still required.

show abstract

“…After administration, the artemisinins are rapidly absorbed, distributed and metabolized. Due to the emergence of resistance to oral artemisinin monotherapy (oAMT), it was replaced with artemisinin-based combination therapies (ACTs) (World Health Organization 2006, in which a fastacting artemisinin derivative is administered together with a slow-acting antimalarial drug of another class of antimalarials (Nigam et al 2019;Mohammadi et al 2020). ACTs are highly effective and efficacious globally and currently remain the recommended first-line treatment for uncomplicated malaria (World Health Organization 2010.…”

Section: Improving the Therapeutic Efficacy Of Artemisininmentioning

confidence: 99%

Enhancing the antimalarial activity of artesunate

et al. 2020

View full text Add to dashboard Cite

The global challenge to the treatment of malaria is mainly the occurrence of resistance of malaria parasites to conventionally used antimalarials. Artesunate, a semisynthetic artemisinin compound, and other artemisinin derivatives are currently used in combination with selected active antimalarial drugs in order to prevent or delay the emergence of resistance to artemisinin derivatives. Several methods, such as preparation of hybrid compounds, combination therapy, chemical modification and the use of synthetic materials to enhance solubility and delivery of artesunate, have been employed over the years to improve the antimalarial activity of artesunate. Each of these methods has advantages it bestows on the efficacy of artesunate. This review discussed the various methods employed in enhancing the antimalarial activity of artesunate and delaying the emergence of resistance of parasite to it.

show abstract

Bioactive Compounds and Health Benefits ofArtemisiaSpecies

Cited by 138 publications

References 107 publications

Artemisia vulgaris efficacies against various stages of Aedes aegypti

Artemisia vulgaris efficacies against various stages of Aedes aegypti

Anti-SARS-CoV Natural Products With the Potential to Inhibit SARS-CoV-2 (COVID-19)

Enhancing the antimalarial activity of artesunate

Contact Info

Product

Resources

About